Five Things to Know About Medicare Site-Neutral Payment Reforms
This brief examines key facts around proposals to align Medicare payments for outpatient services across care settings, otherwise known as “site-neutral payment reforms.”
View the Latest: Prices
Filter
-
-
Prescription Drugs’ Sizable Share of Health Spending
From Drew AltmanIn this column for The Wall Street Journal’s Think Tank, Drew Altman explains why prescription drug spending may be a larger share of health spending than most people think, depending on how you look at it.
-
How High Drug Prices Weigh on the Sickest Americans
From Drew AltmanIn this column for The Wall Street Journal's Think Tank, Drew Altman explores the data behind public concern about prescription drug costs and highlights that the people most in need are the most burdened by the problem.
-
Health of the Healthcare System: An Overview
FeatureThis slideshow accompanies the video, “Health of the Healthcare System,” a diagnostic look at the state of the U.S. healthcare system. It compares the United States to other countries in four key areas: health, quality of health care, cost of care, and accessibility.
-
A New Way of Measuring Health Costs Sheds Light on Recent Health Spending Trends
Issue BriefNational health spending started to grow more rapidly recently after several years of unusually slow growth. This analysis from the Kaiser Family Foundation and the federal Bureau of Economic Analysis helps to dissect why that may be happening. Using recently-released disease-based health spending data compiled by the federal government, the analysis finds that the drivers of health spending growth shifted in the years following the Great Recession. The number of people treated for various diseases picked up,…
-
Why Data on Health-Care Price Variation Doesn’t Itself Solve the Problem
From Drew AltmanIn this column for The Wall Street Journal's Think Tank, Drew Altman discusses a new Blue Cross Blue Shield Association report on “extreme price variation” in health care services and the limits of consumer information as a solution to the problem.
-
Prescription Drugs’ Sizable Share of Health Spending
News ReleaseIn his latest column for The Wall Street Journal‘s Think Tank, Drew Altman explains why prescription drug spending may be a larger share of health spending than most people think, depending on how you look at it. All previous columns by Drew Altman are online.
-
How Many People with Employer-Sponsored Insurance Use the Drugs Slated for Medicare Price Negotiations
Issue BriefAmong the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations, according to a new analysis. The most used drug for people with employer-sponsored health insurance was Jardiance, a drug used to treat diabetes and heart failure, which was taken by more than 911,000 enrollees. The analysis uses the Merative MarketScan 2022 commercial claims to estimate the number of enrollees…
-
How Do Prescription Drug Costs in the United States Compare to Other Countries?
FeatureThis chart collection examines what we know about prescription drug spending and use in the U.S. and comparably large and wealthy countries, using data from the Organization for Economic Cooperation and Development (OECD).
-
Prices Increased Faster Than Inflation for Half of all Drugs Covered by Medicare in 2020
Issue BriefRecent legislation would require drug companies to pay rebates to the federal government when annual increases in prescription drug prices for Medicare and private insurance exceed the rate of inflation. As context for understanding the possible impact of this proposal, this analysis compares price changes for drugs covered by Medicare Part B (administered by physicians) and Part D (retail prescription drugs) between 2019 and 2020 to the inflation rate over the same period.